Company intelligence / Profile preview

Saghmos Therapeutics

Greenwich, Connecticut, United Statesbioct.org ↗

Ownership: Private
Development stage: Phase 3

Overview

Saghmos Therapeutics’ lead product ST‑62516 (trimetazidine) has robust data from use outside the US in cardiac indications. The company aims to demonstrate efficacy in reducing the risk of major adverse cardiac and kidney events following PCI—a significant unmet need with no current FDA-approved therapies. The company has announced collaboration with Duke Clinical Research Institute to optimize its pivotal Phase III trial design. As of early/mid‑2024, they are seeking funding and partners for this study

Therapeutic areas: Cardiovascular
Modalities: Small molecules (specifically trimetazidine)
Industry: Biotech

Drug pipeline

1 asset

trimetazidine

Phase 3

Indications: Acute kidney injury, Major adverse cardiac and kidney events, Cardiorenal complications after PCI, Unstable angina

Partnerships

Duke Clinical Research Institute—collaboration on optimizing/operationalizing the pivotal Phase III trial for ST‑62516

Beyond the preview

Go deeper on Saghmos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saghmos Therapeutics.

Explore the full profile